Insulet ((PODD)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Insulet Corporation is conducting a clinical study titled ‘Safety and Effectiveness of the Omnipod® 5 SmartAdjust 2.0 System in Individuals With Type 1 and Type 2 Diabetes.’ The primary goal is to assess the safety and effectiveness of the Omnipod 5 SmartAdjust 2.0 System for individuals aged 2-70 with diabetes, a significant step in diabetes management technology.
The study focuses on the Omnipod 5 SA2.0 System, a device designed to automate insulin delivery based on Continuous Glucose Monitoring (CGM) values, aiming to improve glucose control for users.
This interventional study follows a single-group model without masking, primarily targeting treatment outcomes. Participants include individuals with Type 1 and Type 2 diabetes, testing the device’s real-world application.
Key dates include the study’s start on August 1, 2024, and its last update on June 10, 2025. These dates are crucial for tracking the study’s progress and potential market entry.
The study’s progress could influence Insulet’s stock performance positively, reflecting investor confidence in innovative diabetes management solutions. Competitors in the diabetes device market may also feel pressure to advance their technologies.
The study is currently recruiting, with ongoing updates available on the ClinicalTrials portal.